/NUVB

NUVB Stock - Nuvation Bio Inc.

Q: What is the analyst price target for NUVB?

Analyst price target information is not currently available for NUVB.

Q: What is NUVB's market cap?

Market capitalization information is not currently available for NUVB.

Healthcare|Biotechnology|NYSE

$6.55+1.47%

+$0.10 (+1.47%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+83.2%upside

Target: $12.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NUVB

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.55

52W High$9.75

52W Low$1.54

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$7.87M	N/A	N/A	N/A	N/A
Gross Profit	$795,000	N/A	N/A	N/A	$-103,000
Gross Margin	10.1%	N/A	N/A	N/A	N/A
Operating Income	$-592,627,000	$-99,822,000	$-119,734,000	$-93,318,000	$-43,551,000
Net Income	$-567,939,000	$-75,802,000	$-104,199,000	$-86,848,000	$-41,659,000
Net Margin	-7213.8%	N/A	N/A	N/A	N/A
EPS	$-2.11	$-0.35	$-0.48	$-0.44	$-0.19

Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Visit Website

Earnings History & Surprises

NUVB

Beat Rate

44%

Last 18 quarters

Avg Surprise

-3.0%

EPS vs Estimate

Beats / Misses

8/5

5 met exactly

Latest EPS

$-0.16

Q4 2025

EPS Surprise History

Q1 24

+40.0%

$-0.06vs$-0.10

Q2 24

+12.5%

$-0.07vs$-0.08

Q3 24

-150.0%

$-0.15vs$-0.06

Q4 24

-15.4%

$-0.15vs$-0.13

Q1 25

-7.1%

$-0.15vs$-0.14

Q2 25

0.0%

$-0.16vs$-0.16

Q3 25

0.0%

$-0.17vs$-0.17

Q4 25

+5.9%

$-0.16vs$-0.17

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 5, 2026	—	—	—	—
Q1 2026	Mar 5, 2026	$-0.11	—	—	—
Q4 2025	Nov 3, 2025	$-0.17	$-0.16	+5.9%	✓ BEAT
Q3 2025	Aug 7, 2025	$-0.17	$-0.17	0.0%	= MET
Q2 2025	May 7, 2025	$-0.16	$-0.16	0.0%	= MET
Q1 2025	Mar 6, 2025	$-0.14	$-0.15	-7.1%	✗ MISS
Q4 2024	Nov 6, 2024	$-0.13	$-0.15	-15.4%	✗ MISS
Q3 2024	Aug 5, 2024	$-0.06	$-0.15	-150.0%	✗ MISS
Q2 2024	May 14, 2024	$-0.08	$-0.07	+12.5%	✓ BEAT
Q1 2024	Feb 29, 2024	$-0.10	$-0.06	+40.0%	✓ BEAT
Q4 2023	Nov 2, 2023	$-0.10	$-0.09	+10.0%	✓ BEAT
Q3 2023	Aug 3, 2023	$-0.11	$-0.09	+18.2%	✓ BEAT
Q2 2023	May 4, 2023	$-0.09	$-0.10	-11.1%	✗ MISS
Q1 2023	Mar 15, 2023	$-0.10	$-0.10	0.0%	= MET
Q4 2022	Nov 3, 2022	$-0.14	$-0.12	+14.3%	✓ BEAT
Q3 2022	Aug 4, 2022	$-0.13	$-0.16	-23.1%	✗ MISS
Q2 2022	May 9, 2022	$-0.15	$-0.10	+33.3%	✓ BEAT
Q1 2022	Feb 28, 2022	$-0.12	$-0.12	0.0%	= MET
Q4 2021	Nov 10, 2021	$-0.11	$-0.11	0.0%	= MET
Q3 2021	Aug 12, 2021	$-0.11	$-0.09	+18.2%	✓ BEAT